HRP20200263T1 - Upotreba derivata pirazolopirimidina za liječenje poremećaja povezanih sa pi3k - Google Patents
Upotreba derivata pirazolopirimidina za liječenje poremećaja povezanih sa pi3k Download PDFInfo
- Publication number
- HRP20200263T1 HRP20200263T1 HRP20200263TT HRP20200263T HRP20200263T1 HR P20200263 T1 HRP20200263 T1 HR P20200263T1 HR P20200263T T HRP20200263T T HR P20200263TT HR P20200263 T HRP20200263 T HR P20200263T HR P20200263 T1 HRP20200263 T1 HR P20200263T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- use according
- methyl
- ethyl
- pharmaceutically acceptable
- Prior art date
Links
- OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 32
- 238000000034 method Methods 0.000 claims 12
- 150000003839 salts Chemical class 0.000 claims 10
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 9
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 claims 6
- 208000031981 Thrombocytopenic Idiopathic Purpura Diseases 0.000 claims 6
- 125000000217 alkyl group Chemical group 0.000 claims 6
- 201000003710 autoimmune thrombocytopenic purpura Diseases 0.000 claims 6
- 125000001475 halogen functional group Chemical group 0.000 claims 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 3
- JFDZBHWFFUWGJE-UHFFFAOYSA-N benzonitrile Chemical compound N#CC1=CC=CC=C1 JFDZBHWFFUWGJE-UHFFFAOYSA-N 0.000 claims 3
- 125000004767 (C1-C4) haloalkoxy group Chemical group 0.000 claims 2
- 125000004765 (C1-C4) haloalkyl group Chemical group 0.000 claims 2
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 claims 2
- 208000035186 Hemolytic Autoimmune Anemia Diseases 0.000 claims 2
- 241000711549 Hepacivirus C Species 0.000 claims 2
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims 2
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims 2
- 241000721454 Pemphigus Species 0.000 claims 2
- 208000007048 Polymyalgia Rheumatica Diseases 0.000 claims 2
- 206010043540 Thromboangiitis obliterans Diseases 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- 201000000448 autoimmune hemolytic anemia Diseases 0.000 claims 2
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims 2
- 125000003709 fluoroalkyl group Chemical group 0.000 claims 2
- 201000003444 follicular lymphoma Diseases 0.000 claims 2
- 210000001102 germinal center b cell Anatomy 0.000 claims 2
- 208000015446 immunoglobulin a vasculitis Diseases 0.000 claims 2
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 claims 2
- 208000021937 marginal zone lymphoma Diseases 0.000 claims 2
- ZQPDJCIXJHUERQ-MNOVXSKESA-N (4r)-4-[3-[(1r)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one Chemical compound CCOC1=C([C@@H](C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1[C@@H]1CNC(=O)C1 ZQPDJCIXJHUERQ-MNOVXSKESA-N 0.000 claims 1
- ZQPDJCIXJHUERQ-QWRGUYRKSA-N (4r)-4-[3-[(1s)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one Chemical compound CCOC1=C([C@H](C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1[C@@H]1CNC(=O)C1 ZQPDJCIXJHUERQ-QWRGUYRKSA-N 0.000 claims 1
- ZQPDJCIXJHUERQ-GHMZBOCLSA-N (4s)-4-[3-[(1r)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one Chemical compound CCOC1=C([C@@H](C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1[C@H]1CNC(=O)C1 ZQPDJCIXJHUERQ-GHMZBOCLSA-N 0.000 claims 1
- ZQPDJCIXJHUERQ-WDEREUQCSA-N (4s)-4-[3-[(1s)-1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one Chemical compound CCOC1=C([C@H](C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1[C@H]1CNC(=O)C1 ZQPDJCIXJHUERQ-WDEREUQCSA-N 0.000 claims 1
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 claims 1
- UCYDWQYLQRHHCX-UHFFFAOYSA-N 4-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]-1,3-oxazolidin-2-one Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1COC(=O)N1 UCYDWQYLQRHHCX-UHFFFAOYSA-N 0.000 claims 1
- ZQPDJCIXJHUERQ-UHFFFAOYSA-N 4-[3-[1-(4-amino-3-methylpyrazolo[3,4-d]pyrimidin-1-yl)ethyl]-5-chloro-2-ethoxy-6-fluorophenyl]pyrrolidin-2-one Chemical compound CCOC1=C(C(C)N2C3=NC=NC(N)=C3C(C)=N2)C=C(Cl)C(F)=C1C1CNC(=O)C1 ZQPDJCIXJHUERQ-UHFFFAOYSA-N 0.000 claims 1
- XGWFJBFNAQHLEF-UHFFFAOYSA-N 9-anthroic acid Chemical compound C1=CC=C2C(C(=O)O)=C(C=CC=C3)C3=CC2=C1 XGWFJBFNAQHLEF-UHFFFAOYSA-N 0.000 claims 1
- 208000032671 Allergic granulomatous angiitis Diseases 0.000 claims 1
- 208000027496 Behcet disease Diseases 0.000 claims 1
- 208000033386 Buerger disease Diseases 0.000 claims 1
- 208000006344 Churg-Strauss Syndrome Diseases 0.000 claims 1
- 208000010007 Cogan syndrome Diseases 0.000 claims 1
- 208000019707 Cryoglobulinemic vasculitis Diseases 0.000 claims 1
- 208000018428 Eosinophilic granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000007465 Giant cell arteritis Diseases 0.000 claims 1
- 206010018372 Glomerulonephritis membranous Diseases 0.000 claims 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 claims 1
- 208000011200 Kawasaki disease Diseases 0.000 claims 1
- 208000034624 Leukocytoclastic Cutaneous Vasculitis Diseases 0.000 claims 1
- 208000032514 Leukocytoclastic vasculitis Diseases 0.000 claims 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 1
- 208000004732 Systemic Vasculitis Diseases 0.000 claims 1
- 208000001106 Takayasu Arteritis Diseases 0.000 claims 1
- 206010047115 Vasculitis Diseases 0.000 claims 1
- 210000003719 b-lymphocyte Anatomy 0.000 claims 1
- 208000010353 central nervous system vasculitis Diseases 0.000 claims 1
- 230000001086 cytosolic effect Effects 0.000 claims 1
- 201000009277 hairy cell leukemia Diseases 0.000 claims 1
- 201000006362 hypersensitivity vasculitis Diseases 0.000 claims 1
- 201000007919 lymphoplasmacytic lymphoma Diseases 0.000 claims 1
- 201000008350 membranous glomerulonephritis Diseases 0.000 claims 1
- 231100000855 membranous nephropathy Toxicity 0.000 claims 1
- 206010063344 microscopic polyangiitis Diseases 0.000 claims 1
- 208000001725 mucocutaneous lymph node syndrome Diseases 0.000 claims 1
- 201000006292 polyarteritis nodosa Diseases 0.000 claims 1
- 206010043207 temporal arteritis Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Claims (19)
1. Spoj za upotrebu u postupku liječenja idiopatske trombocitopenične purpure (ITP), autoimune hemolitične anemije, Behçetove bolesti, Coganovog sindroma, arteritisa divovskih stanica, reumatske polimialgije (PMR), Takayasuvog arteritisa, Buergerove bolesti (lat. thromboangiitis obliterans), vaskulitisa središnjeg živčanog sustava Kawasaki bolesti, poliarteritis nodoze, Churg-Straussovog sindroma, miješanog krioglobulinemičnog vaskulitisa (esencijalnog ili induciranog virusom hepatitisa C (HCV)), Henoch-Schönleinove purpure (HSP), hipersenzitivnog vaskulitisa, mikroskopskog poliangiitisa, Wegenerove granulomatoze, antineutrofilnih citoplazmatskih anititijela povezanih sa (ANCA) sistemskim vaskulitisom (AASV), pemfigusa, membranske nefropatije, kronične limfocitne leukemije (CLL), leukemije dlakavih stanica, limfoma stanice plašta, malog limfocitnog limfoma, folikularnog limfoma, limfoplazmacitnog limfoma, ekstranodalnog limfoma marginalne zone, difuznog B-velikostaničnog limfoma sličnog aktiviranoj B-stanici (ABC), ili difuznog B-velikostaničnog limfoma B-stanice germinalnog centra (GCB) kod pacijenta, gdje je Spoj Formule IV:
[image]
ili njegova farmaceutski prihvatljiva sol, gdje:
G je NH, n je 1, i V je O; ili
G je NH, n je 0, i V je CH2; ili
G je O, n je 0 i V je NH;
R2 je C1-6 alkil ili C1-6 haloalkil;
R4 je halo, OH, CN, C1-4 alkil, C1-4 haloalkil, C1-4 alkoksi, ili C1-4 haloalkoksi;
R5 je halo, OH, CN, C1-4 alkil, C1-4 haloalkil, C1-4 alkoksi, ili C1-4 haloalkoksi.
2. Spoj za upotrebu prema zahtjevu 1, gdje:
a) R2 je C1-3 alkil ili C1-3 fluoroalkil; ili
b) R2 je metil, etil, ili 2,2-difluorometil; ili
c) R2 je metil; ili
d) R2 je etil.
3. Spoj za upotrebu prema zahtjevu 1 ili 2, gdje:
a) R4 je halo, CN, ili C1-3 alkil; ili
b) R4 je F, Cl, CN, ili metil; ili
c) R4 je F; ili
d) R4 je Cl; ili
e) R4 je CN; ili
f) R4 je metil.
4. Spoj za upotrebu prema bilo kojem od zahtjeva 1 do 3, gdje:
a) R5 je halo, CN, ili C1-3 alkil; ili
b) R5 je Cl, CN, ili metil; ili
c) R5 je Cl; ili
d) R5 je CN; ili
e) R5 je metil.
5. Spoj za upotrebu prema zahtjevu 1, gdje:
R2 je C1-3 alkil ili C1-3 fluoroalkil;
R4 je halo, CN, ili C1-3 alkil; i
R5 je halo, CN, ili C1-3 alkil.
6. Spoj za upotrebu prema zahtjevu 1, gdje:
R2 je metil, etil, ili 2,2-difluorometil;
R4 je F, Cl, CN, ili metil; i
R5 je Cl, CN, ili metil;
7. Spoj za upotrebu prema bilo kojem od zahtjeva 1 do 6, gdje:
a) Spoj je Spoj Formule IVa:
[image]
ili njegova farmaceutski prihvatljiva sol; ili
b) Spoj je Spoj Formule IVb:
[image]
ili njegova farmaceutski prihvatljiva sol; ili
c) Spoj je Spoj Formule IVc:
[image]
ili njegova farmaceutski prihvatljiva sol.
8. Spoj za upotrebu prema zahtjevu 1, gdje je Spoj izabran od:
4-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil} pirolidin-2-ona;
4-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-6-kloro-3-etoksi-2-(5-oksopirolidin-3-il)benzonitrila; i
4-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}-1,3-oksazolidin-2-ona;
ili farmaceutski prihvatljive soli bilo kojeg od gore spomenutog.
9. Spoj za upotrebu prema zahtjevu 1, gdje je postupak postupak za liječenje idiopatske trombocitopenične purpure (ITP) izabrane od relapsirane ITP i refraktorne ITP.
10. Spoj za upotrebu prema zahtjevu 1, gdje je postupak postupak za liječenje pemfigusa.
11. Spoj za upotrebu prema zahtjevu 1, gdje je postupak postupak za liječenje autoimune hemolitičke anemije.
12. Spoj za upotrebu prema zahtjevu 1, gdje je postupak postupak za liječenje limfoma stanica plašta.
13. Spoj za upotrebu prema zahtjevu 1, gdje je postupak postupak za liječenje folikularnog limfoma.
14. Spoj za upotrebu prema zahtjevu 1, gdje je postupak postupak za liječenje ekstranodalnog limfoma marginalne zone.
15. Spoj za upotrebu prema bilo kojem od zahtjeva 1 do 14, gdje je Spoj 4-{3-[1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}pirolidin-2-on, ili njegova farmaceutski prihvatljiva sol.
16. Spoj za upotrebu prema zahtjevu 15, gdje je Spoj (R)-4-{3-[(R)-1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}pirolidin-2-on, ili njegova farmaceutski prihvatljiva sol.
17. Spoj za upotrebu prema zahtjevu 15, gdje je Spoj (R)-4-{3-[(S)-1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}pirolidin-2-on, ili njegova farmaceutski prihvatljiva sol.
18. Spoj za upotrebu prema zahtjevu 15, gdje je Spoj (S)-4-{3-[(R)-1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}pirolidin-2-on, ili njegova farmaceutski prihvatljiva sol.
19. Spoj za upotrebu prema zahtjevu 15, gdje je Spoj (S)-4-{3-[(S)-1-(4-amino-3-metil-1H-pirazolo[3,4-d]pirimidin-1-il)etil]-5-kloro-2-etoksi-6-fluorofenil}pirolidin-2-on, ili njegova farmaceutski prihvatljiva sol.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361771480P | 2013-03-01 | 2013-03-01 | |
EP14710739.5A EP2961410B1 (en) | 2013-03-01 | 2014-02-28 | Use of pyrazolopyrimidine derivatives for the treatment of pi3k related disorders |
PCT/US2014/019372 WO2014134426A1 (en) | 2013-03-01 | 2014-02-28 | USE OF PYRAZOLOPYRIMIDINE DERIVATIVES FOR THE TREATMENT OF PI3Kδ RELATED DISORDERS |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20200263T1 true HRP20200263T1 (hr) | 2020-05-29 |
Family
ID=50288319
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20200263TT HRP20200263T1 (hr) | 2013-03-01 | 2020-02-17 | Upotreba derivata pirazolopirimidina za liječenje poremećaja povezanih sa pi3k |
Country Status (32)
Country | Link |
---|---|
US (5) | US9932341B2 (hr) |
EP (3) | EP4233869A3 (hr) |
JP (4) | JP6545106B2 (hr) |
KR (4) | KR20230145517A (hr) |
CN (2) | CN105120871B (hr) |
AR (1) | AR094964A1 (hr) |
AU (4) | AU2014223257B2 (hr) |
BR (1) | BR112015020941A2 (hr) |
CA (1) | CA2901993C (hr) |
CL (1) | CL2015002442A1 (hr) |
CR (1) | CR20150472A (hr) |
CY (1) | CY1122712T1 (hr) |
DK (1) | DK2961410T3 (hr) |
EA (2) | EA202192151A1 (hr) |
ES (2) | ES2774436T3 (hr) |
HK (1) | HK1221398A1 (hr) |
HR (1) | HRP20200263T1 (hr) |
HU (1) | HUE047719T2 (hr) |
IL (5) | IL301180A (hr) |
LT (1) | LT2961410T (hr) |
MX (2) | MX367713B (hr) |
MY (1) | MY177875A (hr) |
PE (1) | PE20151996A1 (hr) |
PH (2) | PH12015501920A1 (hr) |
PL (1) | PL2961410T3 (hr) |
PT (1) | PT2961410T (hr) |
RS (1) | RS59958B1 (hr) |
SG (3) | SG10201912275YA (hr) |
SI (1) | SI2961410T1 (hr) |
TW (4) | TWI657090B (hr) |
UA (1) | UA119641C2 (hr) |
WO (1) | WO2014134426A1 (hr) |
Families Citing this family (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR077280A1 (es) | 2009-06-29 | 2011-08-17 | Incyte Corp | Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden |
SI2751109T1 (sl) | 2011-09-02 | 2017-03-31 | Incyte Holdings Corporation | Heterociklilamini kot inhibitorji pi3k |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
JP6437452B2 (ja) | 2013-01-14 | 2018-12-12 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pimキナーゼ阻害剤として有用な二環式芳香族カルボキサミド化合物 |
ME03780B (me) | 2013-01-15 | 2021-04-20 | Incyte Holdings Corp | Jedinjenja tiazolkarboksamida i piridinkarboksamida korisna kao inhibitori pim kinaze |
TWI657090B (zh) * | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
WO2015027124A1 (en) | 2013-08-23 | 2015-02-26 | Incyte Corporation | Furo- and thieno-pyridine carboxamide compounds useful as pim kinase inhibitors |
KR20220066179A (ko) | 2014-04-08 | 2022-05-23 | 인사이트 코포레이션 | Jak 및 pi3k 억제제 조합에 의한 b-세포 악성종양의 치료 |
WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
US9822124B2 (en) | 2014-07-14 | 2017-11-21 | Incyte Corporation | Bicyclic heteroaromatic carboxamide compounds useful as Pim kinase inhibitors |
US9580418B2 (en) | 2014-07-14 | 2017-02-28 | Incyte Corporation | Bicyclic aromatic carboxamide compounds useful as Pim kinase inhibitors |
WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
CN117800973A (zh) | 2015-02-27 | 2024-04-02 | 因赛特控股公司 | Pi3k抑制剂的盐及其制备方法 |
US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
US9540347B2 (en) | 2015-05-29 | 2017-01-10 | Incyte Corporation | Pyridineamine compounds useful as Pim kinase inhibitors |
AR105967A1 (es) | 2015-09-09 | 2017-11-29 | Incyte Corp | Sales de un inhibidor de pim quinasa |
TW201718546A (zh) | 2015-10-02 | 2017-06-01 | 英塞特公司 | 適用作pim激酶抑制劑之雜環化合物 |
TWI744256B (zh) | 2015-11-06 | 2021-11-01 | 美商英塞特公司 | 作為PI3K-γ抑制劑之雜環化合物 |
ES2833955T3 (es) | 2016-01-05 | 2021-06-16 | Incyte Corp | Piridinas sustituidas con pirazol/imidazol como inhibidores de PI3K-Gamma |
ES2823190T3 (es) | 2016-03-31 | 2021-05-06 | Oncternal Therapeutics Inc | Análogos de indolina y usos de los mismos |
WO2017223414A1 (en) | 2016-06-24 | 2017-12-28 | Incyte Corporation | HETEROCYCLIC COMPOUNDS AS PI3K-γ INHIBITORS |
SG11202003428VA (en) | 2017-10-18 | 2020-05-28 | Incyte Corp | Condensed imidazole derivatives substituted by tertiary hydroxy groups as pi3k-gamma inhibitors |
US10596161B2 (en) | 2017-12-08 | 2020-03-24 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
ES2933820T3 (es) * | 2018-01-10 | 2023-02-14 | Idorsia Pharmaceuticals Ltd | Derivados de 2,4,6,7-tetrahidro-pirazolo[4,3-d]pirimidina-5-ona y compuestos relacionados como moduladores del receptor c5a para el tratamiento de la vasculitis y las enfermedades inflamatorias |
ES2910071T3 (es) | 2018-03-08 | 2022-05-11 | Incyte Corp | Compuestos de aminopirazina diol como inhibidores de PI3K-Y |
SG11202011680YA (en) * | 2018-06-01 | 2020-12-30 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
CN110833552A (zh) * | 2018-08-15 | 2020-02-25 | 广西梧州制药(集团)股份有限公司 | 吡唑并嘧啶衍生物在治疗狼疮肾炎的用途 |
CR20210165A (es) * | 2018-09-05 | 2021-10-01 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3-quinasa (pi3k) campo técnico |
WO2022115120A1 (en) | 2020-11-30 | 2022-06-02 | Incyte Corporation | Combination therapy with an anti-cd19 antibody and parsaclisib |
TW202241436A (zh) | 2020-11-30 | 2022-11-01 | 美商英塞特公司 | 抗cd19抗體及帕薩昔布(parsaclisib)之組合療法 |
CN112808550B (zh) * | 2020-12-28 | 2021-10-01 | 青岛理工大学 | 用于海洋工程的劣化免疫仿生防护界面及制备方法 |
AR127966A1 (es) | 2021-12-16 | 2024-03-13 | Incyte Corp | Formulaciones tópicas de inhibidores de pi3k-delta |
Family Cites Families (36)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
ATE459616T1 (de) | 1998-08-11 | 2010-03-15 | Novartis Ag | Isochinoline derivate mit angiogenesis-hemmender wirkung |
US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
CN1321628C (zh) | 2000-06-28 | 2007-06-20 | 史密斯克莱·比奇曼公司 | 湿磨方法 |
DE60230890D1 (de) | 2001-09-19 | 2009-03-05 | Aventis Pharma Sa | Indolizine als kinaseproteinhemmer |
IL161156A0 (en) | 2001-10-30 | 2004-08-31 | Novartis Ag | Staurosporine derivatives as inhibitors of flt3 receptor tyrosine kinase activity |
PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
TW200610762A (en) | 2004-06-10 | 2006-04-01 | Irm Llc | Compounds and compositions as protein kinase inhibitors |
AU2005309019A1 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors |
TW200916447A (en) | 2007-08-29 | 2009-04-16 | Methylgene Inc | Sirtuin inhibitors |
AR073651A1 (es) * | 2008-09-24 | 2010-11-24 | Novartis Ag | Formulaciones galenicas de compuestos organicos |
CA2738429C (en) * | 2008-09-26 | 2016-10-25 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
AR077280A1 (es) | 2009-06-29 | 2011-08-17 | Incyte Corp | Pirimidinonas como inhibidores de pi3k, y composiciones farmaceuticas que los comprenden |
WO2011025889A1 (en) | 2009-08-28 | 2011-03-03 | Takeda Pharmaceutical Company Limited | HEXAHYDROOXAZINOPTERINE COMPOUNDS FOR USE AS mTOR INHIBITORS |
WO2011075643A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted heteroaryl fused derivatives as pi3k inhibitors |
WO2011075630A1 (en) | 2009-12-18 | 2011-06-23 | Incyte Corporation | Substituted fused aryl and heteroaryl derivatives as pi3k inhibitors |
EP2558463A1 (en) | 2010-04-14 | 2013-02-20 | Incyte Corporation | Fused derivatives as i3 inhibitors |
US9062055B2 (en) | 2010-06-21 | 2015-06-23 | Incyte Corporation | Fused pyrrole derivatives as PI3K inhibitors |
TW201249844A (en) | 2010-12-20 | 2012-12-16 | Incyte Corp | N-(1-(substituted-phenyl)ethyl)-9H-purin-6-amines as PI3K inhibitors |
ES2734878T3 (es) | 2011-02-01 | 2019-12-12 | Univ Illinois | Derivados de N-hidroxibenzamida como inhibidores de HDAC y métodos terapéuticos que utilizan los mismos |
WO2012125629A1 (en) | 2011-03-14 | 2012-09-20 | Incyte Corporation | Substituted diamino-pyrimidine and diamino-pyridine derivatives as pi3k inhibitors |
WO2012135009A1 (en) | 2011-03-25 | 2012-10-04 | Incyte Corporation | Pyrimidine-4,6-diamine derivatives as pi3k inhibitors |
SI2751109T1 (sl) | 2011-09-02 | 2017-03-31 | Incyte Holdings Corporation | Heterociklilamini kot inhibitorji pi3k |
AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
TWI657090B (zh) * | 2013-03-01 | 2019-04-21 | 英塞特控股公司 | 吡唑并嘧啶衍生物治療PI3Kδ 相關病症之用途 |
WO2015191677A1 (en) * | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
CN117800973A (zh) * | 2015-02-27 | 2024-04-02 | 因赛特控股公司 | Pi3k抑制剂的盐及其制备方法 |
SG11202011680YA (en) * | 2018-06-01 | 2020-12-30 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
US11161838B2 (en) * | 2018-11-13 | 2021-11-02 | Incyte Corporation | Heterocyclic derivatives as PI3K inhibitors |
-
2014
- 2014-02-27 TW TW103106906A patent/TWI657090B/zh active
- 2014-02-27 TW TW108100664A patent/TWI687220B/zh active
- 2014-02-27 TW TW110124946A patent/TW202214254A/zh unknown
- 2014-02-27 TW TW109104878A patent/TWI736135B/zh active
- 2014-02-28 PE PE2015001833A patent/PE20151996A1/es not_active Application Discontinuation
- 2014-02-28 AR ARP140100679A patent/AR094964A1/es unknown
- 2014-02-28 MX MX2015011273A patent/MX367713B/es active IP Right Grant
- 2014-02-28 SG SG10201912275YA patent/SG10201912275YA/en unknown
- 2014-02-28 EP EP23161858.8A patent/EP4233869A3/en active Pending
- 2014-02-28 UA UAA201509435A patent/UA119641C2/uk unknown
- 2014-02-28 CA CA2901993A patent/CA2901993C/en active Active
- 2014-02-28 MY MYPI2015002108A patent/MY177875A/en unknown
- 2014-02-28 KR KR1020237033761A patent/KR20230145517A/ko not_active Application Discontinuation
- 2014-02-28 ES ES14710739T patent/ES2774436T3/es active Active
- 2014-02-28 US US14/193,481 patent/US9932341B2/en active Active
- 2014-02-28 EP EP19208523.1A patent/EP3632442B1/en active Active
- 2014-02-28 EP EP14710739.5A patent/EP2961410B1/en active Active
- 2014-02-28 AU AU2014223257A patent/AU2014223257B2/en active Active
- 2014-02-28 WO PCT/US2014/019372 patent/WO2014134426A1/en active Application Filing
- 2014-02-28 SG SG11201506654UA patent/SG11201506654UA/en unknown
- 2014-02-28 KR KR1020217027697A patent/KR102454308B1/ko active IP Right Grant
- 2014-02-28 PL PL14710739T patent/PL2961410T3/pl unknown
- 2014-02-28 JP JP2015560346A patent/JP6545106B2/ja active Active
- 2014-02-28 EA EA202192151A patent/EA202192151A1/ru unknown
- 2014-02-28 RS RS20200176A patent/RS59958B1/sr unknown
- 2014-02-28 LT LTEP14710739.5T patent/LT2961410T/lt unknown
- 2014-02-28 EA EA201591612A patent/EA201591612A1/ru unknown
- 2014-02-28 SI SI201431449T patent/SI2961410T1/sl unknown
- 2014-02-28 BR BR112015020941A patent/BR112015020941A2/pt not_active Application Discontinuation
- 2014-02-28 DK DK14710739.5T patent/DK2961410T3/da active
- 2014-02-28 IL IL301180A patent/IL301180A/en unknown
- 2014-02-28 SG SG10201707130UA patent/SG10201707130UA/en unknown
- 2014-02-28 CN CN201480021187.1A patent/CN105120871B/zh active Active
- 2014-02-28 KR KR1020227035039A patent/KR102586858B1/ko active IP Right Grant
- 2014-02-28 CN CN201810796220.8A patent/CN109010343A/zh active Pending
- 2014-02-28 HU HUE14710739A patent/HUE047719T2/hu unknown
- 2014-02-28 PT PT147107395T patent/PT2961410T/pt unknown
- 2014-02-28 KR KR1020157027010A patent/KR102298150B1/ko active IP Right Grant
- 2014-02-28 ES ES19208523T patent/ES2945212T3/es active Active
-
2015
- 2015-08-24 IL IL240784A patent/IL240784B/en not_active IP Right Cessation
- 2015-08-28 MX MX2019010422A patent/MX2019010422A/es unknown
- 2015-08-31 CL CL2015002442A patent/CL2015002442A1/es unknown
- 2015-09-01 PH PH12015501920A patent/PH12015501920A1/en unknown
- 2015-09-10 CR CR20150472A patent/CR20150472A/es unknown
-
2016
- 2016-06-07 HK HK16106523.5A patent/HK1221398A1/zh unknown
-
2018
- 2018-03-02 US US15/910,708 patent/US20190040067A1/en not_active Abandoned
- 2018-11-14 AU AU2018264053A patent/AU2018264053B2/en active Active
-
2019
- 2019-04-25 JP JP2019084393A patent/JP6776399B2/ja active Active
- 2019-06-11 PH PH12019501321A patent/PH12019501321A1/en unknown
- 2019-07-04 IL IL267853A patent/IL267853B/en active IP Right Grant
-
2020
- 2020-02-17 HR HRP20200263TT patent/HRP20200263T1/hr unknown
- 2020-02-26 CY CY20201100177T patent/CY1122712T1/el unknown
- 2020-05-19 IL IL274771A patent/IL274771A/en unknown
- 2020-07-31 AU AU2020210278A patent/AU2020210278B2/en active Active
- 2020-10-07 JP JP2020169551A patent/JP7189185B2/ja active Active
-
2021
- 2021-06-13 IL IL283943A patent/IL283943B2/en unknown
- 2021-06-30 US US17/364,695 patent/US20210332059A1/en active Pending
- 2021-06-30 US US17/364,551 patent/US20220106318A1/en active Pending
- 2021-06-30 US US17/364,585 patent/US20220119393A1/en active Pending
-
2022
- 2022-08-16 AU AU2022218495A patent/AU2022218495A1/en active Pending
- 2022-12-01 JP JP2022192954A patent/JP2023036609A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20200263T1 (hr) | Upotreba derivata pirazolopirimidina za liječenje poremećaja povezanih sa pi3k | |
HRP20191579T1 (hr) | Spojevi kao modulatori za ror gama | |
JP2016510035A5 (hr) | ||
HRP20180331T1 (hr) | Spojevi n-pirolidinil, n'pirazolil- urea, tiourea, gvanidin i cijanogvanidin kao inhibitori trka kinaze | |
HRP20161613T1 (hr) | Tvari bicikličke ureje, tioureje, gvanidina i cijanogvanidina korisne za liječenje boli | |
HRP20200274T1 (hr) | Terapeutski aktivni spojevi i postupci njihove uporabe | |
HRP20210119T1 (hr) | Derivati bipirazola kao jak inhibitori | |
HRP20170456T1 (hr) | Novi kondenzirani derivati pirimidina, namijenjeni inhibiranju aktivnosti tirozinske kinaze | |
HRP20170017T1 (hr) | Inhibitori tirozin kinaze | |
RU2020123547A (ru) | Соединения и композиции для модуляции киназной активности мутантов egfr | |
PE20220253A1 (es) | Benzamidas sustituidas con 1,3-tiazol-2-ilo | |
JP2018515438A5 (hr) | ||
HRP20140814T1 (hr) | Inhibitori jak2 i njihova uporaba za lijeäśenje mijeloproliferativnih bolesti i karcinoma | |
JP2019081762A5 (hr) | ||
AR080032A1 (es) | Compuestos de pirazol como antagonistas de crth2 | |
HRP20140061T1 (hr) | Antagonisti histaminskog receptora h3 | |
RU2017111200A (ru) | Циклогексилэтилзамещенные диаза- и триаза-трициклические соединения в качестве антагонистов индоламин-2,3-диоксигеназы для лечения рака | |
SI2978752T1 (en) | 6- (5-Hydroxy-1H-pyrazol-1-yl) nicotinamide derivatives and their use as inhibitors of PHD | |
RU2016136116A (ru) | Фармацевтические соединения | |
EA201591703A1 (ru) | Замещенные 2-азабициклы и их применение в качестве модуляторов рецепторов орексина | |
SI2861579T1 (en) | Benzamide derivatives for inhibiting the activity of ABL1, ABL2 and BCR-ABL1 | |
AR088029A1 (es) | Compuestos de pirimidina sustituidos, composiciones farmaceuticas que los contienen y uso de los mismos para el tratamiento del dolor, accidentes cerebrovasculares, epilepsia y otras enfermedades del sistema nervioso central | |
RU2016103938A (ru) | Модуляторы протеин-тирозинкиназы и способы их применения | |
RU2014152257A (ru) | Гетероциклильные пиримидиновые аналоги в качестве ингибиторов tyk2 | |
HRP20120202T1 (hr) | AMIDOFENOKSIINDAZOLI, KORISNI KAO INHIBITORI c-MET |